Silvaco Group SEC Filings

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).

The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.

Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.

Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA – FURMO-006) is scheduled to begin 2H 2025.

Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.

Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.

Timeline: closing and delivery are expected on or about 3 July 2025.

Synchrony Financial (SYF) filed a Form 4 on 2 Jul 2025 disclosing a routine equity award to director Fernando Aguirre. On 30 Jun 2025 Aguirre received 825 restricted stock units (RSUs) classified under transaction code “A” (grant). The filing lists an indicative price of $66.74, though RSUs do not require cash payment. The award will vest in full on 30 Jun 2026; each RSU converts into one share of SYF common stock.

Following the grant, Aguirre’s direct ownership rises to 27,097 common shares. He also reports 15,300 shares held indirectly through family trusts, bringing his total reported economic exposure to 42,397 shares. No open-market purchases, sales, or derivative transactions were reported, and there were no amendments to previous filings.

The size of the award represents a modest increase—roughly 3% of Aguirre’s previously reported direct holdings and an immaterial fraction of SYF’s ~420 million shares outstanding. As such, the transaction is viewed as a standard board compensation event that marginally aligns director incentives with shareholder interests but carries no material impact on the company’s capital structure or valuation.

Borr Drilling Limited (BORR) has launched a preliminarily marketed public offering of 50 million common shares via a two-step settlement structure. Approximately 30 million shares are expected to settle on 7 July 2025 (the “First Settlement”) while the remaining 20 million will settle on or about 7 August 2025 (the “Second Settlement”) only if shareholders approve an increase in authorised share capital at a Special General Meeting (SGM) on 6 August 2025. The shares are listed on the NYSE; the last reported price on 1 July 2025 was $1.95.

Net proceeds—whose exact amount will depend on final pricing—are earmarked for general corporate purposes such as debt service, capital expenditure and working-capital needs. The equity raise is also a condition precedent for agreed amendments to Borr’s financing package: commitments have been received to lift the Super Senior Revolving Credit Facility to $200 million (+$50 million), re-classify the $45 million guarantee line, and add a new $34 million senior secured RCF, jointly raising available liquidity by more than $100 million and easing covenant thresholds (lower liquidity minimum, higher leverage ceiling, lower coverage ratios).

Operationally, Borr has booked 13 new contract awards/LOIs/LOAs in 2025, adding ~3,010 potential rig-days and $366 million of revenue backlog (average day-rate $121k). Contract coverage now stands at 84% for 2025 and 45% for 2026 at average day-rates of $144k and $141k, respectively.

Leadership refresh: CCO Bruno Morand will become CEO on 1 September 2025; current CEO Patrick Schorn will transition to Executive Chair, while Chairman Tor Olav Trøim will remain on the board. Investor Granular Capital’s CIO, Thiago Mordehachvili, is nominated to join the board, contingent on SGM approval to expand board size.

Several insiders—Schorn ($1 m), Morand ($0.3 m) and Drew Holding Ltd. ($10 m)—intend to subscribe, all electing to receive shares in the Second Settlement. If the SGM fails, only the First Settlement closes, leaving the remaining 20 million shares undelivered.